




CVE-2014-6721

Published on: 09/26/2014 12:00:00 AM UTC

Last Modified on: 03/23/2021 11:25:55 PM UTC

CVE-2014-6721

[Source: Mitre](#)[Source: NIST](#)[CVE.ORG](#)[Print: PDF](#) 

Certain versions of [Pharmaguideline](#) from [Pharmaguideline](#) contain the following vulnerability:

The Pharmaguideline (aka com.pharmaguideline) application 1.2.0 for Android does not verify X.509 certificates from SSL servers, which allows man-in-the-middle attackers to spoof servers and obtain sensitive information via a crafted certificate.

CVE-2014-6721 has been assigned by cert@cert.org to track the vulnerability

CVSS2 Score: **5.4 - MEDIUM**

Access
Vector

Access
Complexity

Authentication

ADJACENT_NETWORK

MEDIUM

NONE

Confidentiality
Impact

Integrity
Impact

Availability
Impact

PARTIAL

PARTIAL

PARTIAL

CVE References

Description

Tags

Link

CERT
Vulnerability
Notes
Database

[US Government Resource](#)
[www.kb.cert.org](#)
[text/html](#)
[Inactive Link](#) [Not Archived](#)

[CERT-VN VU#819305](#)

VU#582497 -
Multiple
Android
applications
fail to properly
validate SSL
certificates

[US Government Resource](#)
[www.kb.cert.org](#)
[text/html](#)

[CERT-VN VU#582497](#)

Android apps
that fail to
validate SSL -
Google Sheets

[docs.google.com](#)
[text/html](#)

[MISC](#)
[docs.google.com/spreadsheets/d/1t5GXwjw82SyunALVJb2w0zi3FoLRIkfGPc7AMjRF0r4/edit?usp=sharing](#)

By selecting these links, you may be leaving CVEreport webspace. We have provided these links to other websites because they may have information that would be of interest to you. No inferences should be drawn on account of other sites being referenced, or not, from this page. There may be other websites that are more appropriate for your purpose. CVEreport does not necessarily endorse the views expressed, or concur with the facts presented on these sites. Further, CVEreport does not endorse any commercial products that may be mentioned on these sites. Please address comments about any linked pages to comment@cve.report.

There are currently no QIDs associated with this CVE

Known Affected Configurations (CPE V2.3)

Type	Vendor	Product	Version	Update	Edition	Language
Application	Pharmaguideline	Pharmaguideline	1.2.0	All	All	All
Application	Pharmaguideline	Pharmaguideline	1.2.0	All	All	All
cpe:2.3:a:pharmaguideline:pharmaguideline:1.2.0:*:*:*:*:android:*:*:						
cpe:2.3:a:pharmaguideline:pharmaguideline:1.2.0:*:*:*:*:android:*:*:						

No vendor comments have been submitted for this CVE

[← Previous ID](#)

[Next ID →](#)

© [CVE.report](#) 2023   |

Use of this information constitutes acceptance for use in an AS IS condition. There are NO warranties, implied or otherwise, with regard to this information or its use. Any use of this information is at the user's risk. It is the responsibility of user to evaluate the accuracy, completeness or usefulness of any information, opinion, advice or other content. EACH USER WILL BE SOLELY RESPONSIBLE FOR ANY consequences of his or her direct or indirect use of this web site. ALL WARRANTIES OF ANY KIND ARE EXPRESSLY DISCLAIMED. This site will NOT BE LIABLE FOR ANY DIRECT, INDIRECT or any other kind of loss.

CVE, CWE, and OVAL are registered trademarks of [The MITRE Corporation](#) and the authoritative source of CVE content is [MITRE's CVE web site](#). This site includes MITRE data granted under the following [license](#).

CVE.report and Source URL Uptime Status [status.cve.report](#)